













LEO Pharma pipeline overview

2019 Q4

Project	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
Dermatology							
Tralokinumab LP0162	An IL-13 anti-inflammatory monoclonal antibody under development for people with atopic dermatitis.	AstraZeneca 					
Oral PDE4i LP0058	An oral anti-inflammatory compound under development for treatment of psoriasis.						
Delgocitinib LP0133	A pan-JAK inhibitor for topical use, under development for people with atopic dermatitis and chronic hand eczema.	JT 					
ARGX-112 LP0145	An anti-inflammatory monoclonal antibody for the treatment of atopic dermatitis.	argenx 					
Oral H4R Antagonist LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist, intended to offer an oral treatment for people with atopic dermatitis.	JW 					
IL-17A PPI LP0200	An IL-17 small-molecule modulator under development for people with psoriasis.						

 Finalised
 Current phase

